Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...
Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
Among patients with diabetes receiving PCI, novel antidiabetic agents may reduce risk for acute kidney injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback